Physician profile
Allison C Eberle
NPI 1073143301
$3,631.27
in general payments reported to CMS, 2019-2025
30 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,909 · 2022: $1,058 · 2023: $45.25 · 2024: $137 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.64 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.79 | 2021-2022 | |
| Pfizer INC. | $172.02 | 2021-2025 | |
| Genzyme Corporation | $151.82 | 2024-2025 | |
| Daiichi Sankyo INC. | $131.49 | 2021-2022 | |
| Gilead Sciences, INC. | $131.38 | 2021-2022 | |
| Qol Medical, LLC | $85.74 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $78.59 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $75.25 | 2021-2022 | |
| Ucb, INC. | $65.73 | 2025 | Bimzelx |
| Boston Scientific Corporation | $57.45 | 2022-2023 | Watchman Access System |
| Nestle Healthcare Nutrition INC. | $55.34 | 2022 | |
| Amgen INC. | $47.42 | 2021-2022 | |
| Organon LLC | $39.38 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $34.02 | 2021 | |
| Vivus LLC | $33.64 | 2021 | |
| Janssen Biotech, INC. | $29.63 | 2025 | Tremfya |
| Pharmacosmos Therapeutics INC. | $28.59 | 2021 | |
| Celgene Corporation | $24.61 | 2021-2022 | |
| Csl Behring | $24.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.45 | 2022 | |
| Ferring Pharmaceuticals INC. | $20.43 | 2021 | |
| Surmodics, INC. | $18.55 | 2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Sublime Microcatheter, 018, 200cm, Straight |
| Leo Pharma INC. | $18.49 | 2024 | Adbry |
| Alnylam Pharmaceuticals INC. | $15.17 | 2021 | |
| Smith+Nephew, INC. | $14.16 | 2025 | Collagenase Santyl, Iodosorb Ointment 40g USA |
| Merck Sharp & Dohme LLC | $13.80 | 2021 | |
| Integra Lifesciences Corporation | $12.92 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Evoke Pharma, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Eberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.